These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1494073)

  • 1. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.
    Ginsberg GM; Shouval D
    J Epidemiol Community Health; 1992 Dec; 46(6):587-94. PubMed ID: 1494073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.
    Ginsberg GM; Berger S; Shouval D
    Bull World Health Organ; 1992; 70(6):757-67. PubMed ID: 1486673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity.
    Ginsber GM; Slater PE; Shouval D
    J Hepatol; 2001 Jan; 34(1):92-9. PubMed ID: 11211913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus.
    Arevalo JA; Washington AE
    JAMA; 1988 Jan; 259(3):365-9. PubMed ID: 2961895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK; Hutton G; Das Dores Pascoal E
    Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic evaluation and prediction of hepatitis B immunization strategy in Shenzhen, China].
    Sun PP; Zhang SX; Xia Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):743-747. PubMed ID: 29996303
    [No Abstract]   [Full Text] [Related]  

  • 7. Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India.
    Prakash C
    Int J Technol Assess Health Care; 2003; 19(1):28-40. PubMed ID: 12701937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of universal newborn hepatitis B vaccination in China.
    Lu SQ; McGhee SM; Xie X; Cheng J; Fielding R
    Vaccine; 2013 Apr; 31(14):1864-9. PubMed ID: 23384752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit analysis of the Polish hepatitis B prevention programme.
    Wiewióra-Pilecka D
    Vaccine; 2000 Feb; 18 Suppl 1():S52-4. PubMed ID: 10683548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of economic outcomes of "hepatitis B vaccine event reported by media" in China, 2013].
    Zhang SX; Sun PP; Xia Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):837-841. PubMed ID: 30107719
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S.
    Miriti MK; Billah K; Weinbaum C; Subiadur J; Zimmerman R; Murray P; Gunn R; Buffington J
    Public Health Rep; 2008; 123(4):504-13. PubMed ID: 18763413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel.
    Ginsberg GM; Kassis I; Dagan R
    J Epidemiol Community Health; 1993 Dec; 47(6):485-90. PubMed ID: 8120505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs and benefits of a second measles inoculation of children in Israel, the West Bank, and Gaza.
    Ginsberg GM; Tulchinsky TH
    J Epidemiol Community Health; 1990 Dec; 44(4):274-80. PubMed ID: 2126028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.
    Margolis HS; Coleman PJ; Brown RE; Mast EE; Sheingold SH; Arevalo JA
    JAMA; 1995 Oct; 274(15):1201-8. PubMed ID: 7563509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of hepatitis B vaccine in The Gambia.
    Hall AJ; Roberston RL; Crivelli PE; Lowe Y; Inskip H; Snow SK; Whittle H
    Trans R Soc Trop Med Hyg; 1993; 87(3):333-6. PubMed ID: 8236411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
    Vimolket T; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-benefit analysis of the introduction of mass vaccination against hepatitis B in Italy.
    Demicheli V; Jefferson TO
    J Public Health Med; 1992 Dec; 14(4):367-75. PubMed ID: 1489561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
    Krahn M; Detsky AS
    Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.